Top entities: Unique Pharmaceutical Laboratories, KC Pharmaceuticals, Rising Pharmaceuticals, United States — Food and Drug Administration, Zantac.

What category does this event fall under?

Regulatory — classified as product recall.

What is the sentiment of coverage?

Aggregate sentiment score: -10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 23, 2026. Coverage continues to evolve.

Regulatory product recall

Cetirizine recall over ranitidine contamination

Q: When did this event occur?

First reported Jul 21, 2026; last updated Jul 23, 2026.

Q: What is the market impact?

General. The recall is limited in scope and no adverse events have been reported, so market impact is minimal.

Q: What were the key actions taken?

Unique Pharmaceutical Laboratories recalled · United States — Food and Drug Administration failed to share · Rising Pharmaceuticals distributed recalled product

Analysis based on 7 articles · First reported Jul 21, 2026 · Last updated Jul 23, 2026

Sentiment

-10

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The recall is limited in scope and no adverse events have been reported, so market impact is minimal. However, it may raise concerns about manufacturing quality at KC Pharmaceuticals and its subsidiaries.

Pharmaceutical

Event Summary

Unique Pharmaceutical Laboratories, a division of KC Pharmaceuticals, voluntarily recalled four lots of Cetirizine Hydrochloride Tablets USP 5 mg (generic Cetirizine) due to possible cross-contamination with ranitidine (generic Zantac). The recall was prompted after a pharmacy technician noticed red dots on tablets. The FDA published the recall announcement on July 20, 2026. No adverse events have been reported. The affected lots were distributed nationwide by Rising Pharmaceuticals The contamination could cause life-threatening allergic reactions in sensitive individuals.

Key Actions

80 Unique Pharmaceutical Laboratories recalled

50 United States — Food and Drug Administration failed to share

40 Rising Pharmaceuticals distributed recalled product

Entities Involved

priv

Unique Pharmaceutical Laboratories

Unique Pharmaceutical Laboratories initiated the voluntary recall of its cetirizine tablets due to potential ranitidine contamination, which could harm its reputation and regulatory standing.

Importance 100.0 Sentiment -20.0

priv

KC Pharmaceuticals

As the parent company of Unique Pharmaceutical Laboratories, KC Pharmaceuticals faces potential reputational damage and scrutiny over manufacturing quality control.

Importance 80.0 Sentiment -15.0

priv

Rising Pharmaceuticals

Rising Pharma Holdings distributed the recalled product nationwide and is coordinating returns, facing logistical and reputational costs.

Importance 70.0 Sentiment -10.0

govactor

United States — Food and Drug Administration

The FDA published the recall announcement and is monitoring the situation, fulfilling its regulatory oversight role.

Importance 60.0 Sentiment 0.0

oth

Zantac

Zantac is the brand name for ranitidine; the contaminant is ranitidine, but no Zantac products are directly involved.

Importance 20.0 Sentiment -5.0

govactor

United States — National Institutes of Health

The NIH is mentioned in one article regarding a 2015 study on cetirizine and ranitidine combination; not directly involved in the recall.

Importance 10.0 Sentiment 0.0

Relationships

KC Pharmaceuticals related ↔ United States — Food and Drug Administration

United States — Food and Drug Administration related ↔ United States — National Institutes of Health

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard